cholestanol has been researched along with Lower Extremity Weakness, Spastic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, YH; Chen, C; Ding, ZT; Gong, LY; Sun, YM; Wang, J; Wu, H; Wu, JJ; Zhang, Y | 1 |
| Clemen, CS; Dodel, R; Klockgether, T; Lütjohann, D; Spottke, EA; Urbach, H; von Bergmann, K | 1 |
2 other study(ies) available for cholestanol and Lower Extremity Weakness, Spastic
| Article | Year |
|---|---|
Clinical and molecular genetic features of cerebrotendinous xanthomatosis patients in Chinese families.
Topics: Adult; Age of Onset; Asian People; Cerebellar Ataxia; Cholestanetriol 26-Monooxygenase; Cholestanol; Cognition Disorders; Disease Progression; Female; Genetic Testing; Humans; Male; Middle Aged; Mutation; Paraparesis, Spastic; Pedigree; Polymerase Chain Reaction; Xanthomatosis; Xanthomatosis, Cerebrotendinous | 2017 |
Cerebrotendinous xanthomatosis: a treatable ataxia.
Topics: Adult; Cerebellar Ataxia; Cerebellum; Chenodeoxycholic Acid; Cholestanol; Cholesterol; Disease Progression; Electroencephalography; Humans; Magnetic Resonance Imaging; Male; Paraparesis, Spastic; Peripheral Nervous System Diseases; Simvastatin; Treatment Outcome; Xanthomatosis, Cerebrotendinous | 2005 |